Stemina Biomarker Discovery
Stemina Biomarker Discovery is one remarkable corporation with two distinct business units—NeuroPointDX, focused on diagnosis and treatment of neurological disorders such as autism spectrum disorder, and Stemina, focused on toxicology.
Stemina screens chemical compounds for toxicity. Its cell-based assays arise from the strategic convergence of two cutting-edge technologies: human embryonic stem (hES) cells or induced pluripotent stem (iPS) cells and metabolomics.
A world leader in building human cellular models for toxicity screening of drug candidates, chemical compounds, and ingredients in cosmetics and tobacco, Stemina Biomarker Discovery has created the first and only developmental toxicity assay that uses a human system for assessing the risk that a compound will cause birth defects if a woman is exposed during pregnancy.